Egypt Hypersomnia Therapeutics Market Analysis

Egypt Hypersomnia Therapeutics Market Executive Summary

The Egypt Hypersomnia Therapeutics Market is at around $14.95 Mn in 2023 and is projected to reach $22.08 Mn in 2030, exhibiting a CAGR of 5.73% during the forecast period.

Hypersomnia is a group of neurological disorders characterized by excessive daytime sleepiness, despite getting enough sleep at night. This can significantly impair daily functioning and reduce quality of life. While the exact causes are still being researched, hypersomnia can be linked to underlying medical conditions, neurological disorders, or disruptions in sleep regulation mechanisms. People with hypersomnia often experience symptoms such as not feeling refreshed upon waking, feeling groggy and slow for extended periods after waking, and an excessive need for sleep despite sleeping for long periods. Chronic headaches, loss of appetite, excessive sweating, and depression have also been reported. Treatment for hypersomnia focuses on managing daytime sleepiness. This can involve adopting healthy lifestyle practices like eating well and exercising regularly. Medications like stimulants can also be prescribed to promote wakefulness. In some cases, cognitive behavioral therapy for insomnia (CBT-I) can help address underlying sleep habits that contribute to hypersomnia.

Egypt faces a significant public health burden due to sleep disorders with an estimated prevalence of 26.2% in females and 14.5% in males of the population. The market therefore is driven by significant factors like the increasing awareness about hypersomnia disorders, an aging demographic, and increasing healthcare expenditure. However, limited treatment options, restricted access to healthcare, and strict regulatory approval impede market growth

The leading pharmaceutical companies include Delt Pharma. Takeda Pharmaceuticals, Teva, and Sedico Pharmaceuticals are also significant contributors to the hypersomnia therapeutics landscape, with continuous research and development activities.

Market Dynamics

Market Growth Drivers

Increasing Awareness about Hypersomnia Disorders: Increased public awareness campaigns and healthcare professional education are leading to more accurate diagnoses, raising the potential patient pool for these medications. The ICOM Group organized the Egyptian Sleep Summit in 2023, which gathered experts to discuss various aspects of sleep medicine and disorders in Egypt.

Expanding Geriatric Population: Hypersomnia can be more prevalent in older adults, due to changes in sleep architecture and underlying health conditions. With the increase in the geriatric population estimated at around 10%, the prevalence of hypersomnia disorders is expected to rise, driving demand for effective treatment options tailored to the unique needs of older adults.

Increasing Healthcare Expenditure: As Egypt's healthcare expenditure increases, more people may have access to health insurance and financial resources needed to afford hypersomnia medications. Increased healthcare spending can also lead to a wider availability of hypersomnia medications in hospitals and clinics. This can make it easier for people to get the specific medication they need.

Market Restraints

Limited Treatment Options: The choice of drugs for hypersomnia is relatively small. This lack of options can be particularly problematic for patients who have a variety of symptoms or who respond differently to different medications. As a result, healthcare providers may struggle to find the most appropriate regimen for individual patients, leading to suboptimal outcomes and patient dissatisfaction.

Strict Regulatory Approval Process: In Egypt, the regulatory pathway for approving new drugs is slow and complex. While this stringent process ensures that only safe and efficacious medications reach the market, it also presents a significant barrier to the timely introduction of novel or more effective treatments. It leaves patients with limited access to cutting-edge solutions that could vastly improve their quality of life.

Restricted access to healthcare: Not everyone in Egypt has access to quality healthcare facilities or specialists who diagnose and treat hypersomnia. This limits the number of people who receive prescriptions for these medications.

Regulatory Landscape and Reimbursement Scenario

Egyptian Drug Authority (EDA) is the primary regulatory body overseeing pharmaceuticals in Egypt. It safeguards public health by ensuring the safety, quality, and efficacy of medicines, biologics, medical devices, cosmetics, and pesticides. The EDA monitors the pharmaceutical market for counterfeit drugs, safety concerns, and adverse reactions. It also contributes to strategic planning for the pharmaceutical industry, aiming for affordability and access to high-quality medicines.

All pharmaceutical products must be approved by the EDA before distribution or marketing in the country. Central Administration for Pharmaceutical Affairs (CAPA) is responsible for the registration and pricing of medicines, as well as the inspection of pharmacies and manufacturing facilities. Within thirty days of the date of the receipt of the preliminary approval of the technical committee, the applicant must submit its file to the pricing committee which in turn will reply within 60 days of receipt of the file. After all the applicant is then issued the final approval which is valid for 10 years from the date of the issuance of the preliminary approval. Investigation.

Egypt has implemented a universal health insurance system, which aims to provide comprehensive healthcare coverage to all citizens. The UHI is managed by the Universal Health Insurance Authority (UHIA).

Competitive Landscape

Key Players

Here are some of the major key players in the Egypt Hypersomnia Therapeutics Market:

• Delta Pharma
• Takeda Pharmaceuticals
• Teva
• Pfizer
• Sedico Pharmaceuticals
• Apex Pharma
• Mylan N.V.
• Fisher and Paykel Healthcare
• GlaxoSmithKline
• Theranexus